Moderna

Current directors and officers who also hold a role at another S&P 500 company.

• Elizabeth G. NabelMDT · Director
• Michael R. McDonnellBAX · Director
• Sandra HorningGILD · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Sep 30, 2026

   (b) and (c) On September 30, 2026, Moderna, Inc. (“Moderna” or the “Company”) announced the appointment of Juan Andres as its Chief Operating Officer (“COO”) effective October 5, 2026. In this newly created role, Mr. Andres will support the increasing scale and diversification of the Company and will report to Chief Executive Officer Stephane Bancel and serve on the Company’s Executive Committee. Mr. Andres, 62, previously spent nearly six years at Moderna, including serving as its Chief Technical Operations and Quality Officer from 2018 through 2022 and as its President, Strategic Partnerships and Enterprise Expansion before retiring from Moderna in 2023.

   Read the 8-K filing
2. Jul 8, 2026

   (d) On July 6, 2026 , the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), appointed Michael McDonnell to the Board, effective July 8, 2026. Mr. McDonnell has more than 35 years of financial leadership and public company experience, most recently serving as Chief Financial Officer of Biogen Inc. from August 2020 through February 2025. He previously served as Chief Financial Officer of IQVIA Holdings Inc., Intelsat S.A., MCG Capital Corporation, and EchoStar Communications. Mr. McDonnell was appointed to serve as a Class II director of the Company, to hold office until the 2029 annual meeting of shareholders or until his earlier death, resignation or removal. Mr.

   Read the 8-K filing
3. Oct 2, 2024

   (d) On September 28, 2024, the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Abbas Hussain to the Board, effective October 2, 2024. Mr. Hussain has decades of leadership and operating experience in healthcare, most recently serving as Chief Executive Officer of Vifor Pharma. He previously served in various leadership roles at GlaxoSmithKline and Eli Lilly and Company. Simultaneously with Mr. Hussain’s appointment, the size of the Board has been fixed at nine directors. Mr. Hussain will serve as a Class II director of the Company, to hold office until the 2026 annual meeting of shareholders or until his earlier death, resignation or removal. Mr. Hussain was also appointed to serve on the Audit Committee of the Board.

   Read the 8-K filing
4. Jul 23, 2024

   (b) On July 19, 2024, Robert Langer and Stephen Berenson each notified Moderna, Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), including all committees on which he serves, effective August 5, 2024. Neither of their decisions to resign was the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Beginning August 5, 2024, Dr. Langer and Mr. Berenson will each provide consulting services to the Company, during which periods their outstanding equity awards will continue to vest; no other compensation is contemplated by the agreements other than reimbursement of reasonable, documented expenses. Under these agreements, each of Dr. Langer and Mr. Berenson has agreed to provide consulting services to the Company through November 1, 2026.

   Read the 8-K filing
5. Dec 12, 2023

   (b) On December 12, 2023, Moderna, Inc. (the “Company”) announced that following a restructuring of the Company’s commercial organization and reporting lines, Arpa Garay, the Company’s Chief Commercial Officer, will be departing the Company, and that effective as of December 8, 2023, Ms. Garay will no longer serve in that role or as an executive officer of the Company. As announced on December 12, 2023, following the restructuring, the Company’s commercial organization will be overseen by the Company’s Chief Executive Officer, Stéphane Bancel, and the Company’s President, Stephen Hoge. Ms. Garay has been asked to remain on as an employee of the Company through June 2024, and to serve in an advisory capacity to Mr. Bancel and Dr. Hoge to assist with the transition. (e) At the time of Ms.

   Read the 8-K filing
6. Sep 29, 2022

   (b) On September 29, 2022, Moderna, Inc. (the “Company”) announced that Juan Andres, the Company’s Chief Technical Operations and Quality Officer, will transition into a new role as President, Strategic Partnerships and Enterprise Expansion of the Company, effective January 1, 2023. In his new role, Mr. Andres will focus on building out the Company’s organization to support its growing pipeline. The Company further announced that Dr. Jerh Collins, Ph.D., who will join the Company on O ctober 3, 2022, will assume the role of Chief Technical Operations and Quality Officer of the Company, effective January 1, 2023. Dr.

   Read the 8-K filing
7. Aug 17, 2022

   (b), (c) and (e) On August 17, 2022, Moderna, Inc. (the “Company”) announced that James Mock has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), beginning September 6, 2022. Following the appointment of Mr. Mock, David Meline will retire as the Company’s CFO effective the same date, but will remain as a consultant to the Company to assist with the transition. Prior to joining the Company, Mr. Mock, 45, served as Senior Vice President and CFO of PerkinElmer, Inc., a life sciences, diagnostics, and analytical solutions company, since May 2018. In his role at PerkinElmer, he had overall leadership responsibility for the strategy and operations of all Company finance functions. During that time, he was instrumental in transforming PerkinElmer into an organization with a strengthened financial profile for growth and profitability. Before that, Mr.

   Read the 8-K filing
8. Jun 1, 2022

   of the Current Report on Form 8-K of Moderna, Inc. (the “Company”) filed on May 11, 2022 (the “Original Form 8-K”) to add the information described herein. The Original Form 8-K was previously amended by the Current Report on Form 8-K/A that the Company filed on May 13, 2022.

   Read the 8-K filing
9. May 13, 2022

   (b) and (e) On May 11, 2022, the Company filed the Original Form 8-K to disclose that, on May 10, 2022, Jorge Gomez departed from the role of Chief Financial Officer of the Company and that he would be provided certain benefits under the Company’s Amended and Restated Executive Severance Plan, comprising (i) 12 months’ salary, totaling $700,000, and (ii) COBRA coverage for 12 months (the “Severance Benefits”). This Current Report on Form 8-K/A hereby amends the Original Form 8-K to disclose that, on May 13, 2022, the Company and Mr. Gomez entered into an Executive Separation Agreement and Release (the “Separation Agreement”). Pursuant to the terms of the Separation Agreement, the Company has the right to terminate or suspend the Severance Benefits and to seek repayment of any and all payments and the value of any benefits made to Mr.

   Read the 8-K filing
10. May 11, 2022

    (b) and (c) On May 10, 2022, Jorge Gomez departed, effective immediately, from the role of Chief Financial Officer of Moderna, Inc. (the “Company”). In connection with Mr. Gomez’s departure, he will be provided certain benefits under the Company’s Amended and Restated Executive Severance Plan, comprising (i) 12 months’ salary, totaling $700,000, and (ii) COBRA coverage for 12 months. Mr. Gomez will forfeit his signing bonus, eligibility for relocation reimbursements, bonus eligibility and his eligibility for new hire equity awards that were disclosed by the Company in a Current Report on Form 8-K on April 11, 2022. Mr. Gomez’s departure follows the public disclosure on May 10, 2022 by Mr. Gomez’s former employer, Dentsply Sirona Inc., of an ongoing internal investigation into certain matters, including financial reporting.

    Read the 8-K filing
11. Apr 11, 2022

    (b), (c) and (e) On April 11, 2022, Moderna, Inc. (the “Company”) announced that Jorge M. Gomez had been appointed to serve as the Company’s Chief Financial Officer (“CFO”), beginning May 9, 2022. Following the appointment of Mr. Gomez, David Meline will retire as the Company’s CFO effective the same date, but will remain as a consultant to the Company to assist with the transition. Prior to joining the Company, Mr. Gomez, 54, served as Executive Vice President and CFO of Dentsply Sirona, a public dental equipment manufacturer and dental consumables producer, since August 2019. Before that, since 2006, Mr. Gomez served in roles of increasing responsibility at Cardinal Health, a public, multinational health care services company, most recently as CFO from January 2018 to August 2019.

    Read the 8-K filing
12. Mar 10, 2021

    On March 10, 2021, the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Elizabeth Nabel, M.D. to the Board, effective that same date. Simultaneously with Dr. Nabel’s appointment, the size of the Board was fixed at nine directors and a third director position was added among the Class III directors. Dr. Nabel will serve as the third Class III director of the Company, to hold office until the 2021 annual meeting of stockholders on April 28, 2021 or until her earlier death, resignation or removal. Dr. Nabel is up for election as a Class III director at the 2021 annual meeting of stockholders. Upon her appointment, Dr. Nabel was also appointed to serve on the Product Development Committee and the Nominating and Corporate Governance Committee of the Board. Dr.

    Read the 8-K filing
13. Jul 30, 2020

    (b) On July 30, 2020, Elizabeth Nabel, M.D. resigned from the Board of Directors of Moderna, Inc. (the “Company”). Dr. Nabel’s decision to resign was not the result of any disagreement with the Company on any matters relating to the Company’s operations, policies or practices.

    Read the 8-K filing
14. Jul 2, 2020

    On June 29, 2020, the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Elizabeth E. Tallett to the Board effective July 1, 2020. Ms. Tallett will serve as a Class III director of the Company, to hold office until the 2021 annual meeting of stockholders or until her earlier death, resignation or removal. Ms. Tallett was also appointed to serve on the Audit Committee of the Board. Upon the appointment of Ms. Tallett to the Audit Committee, Dr. François Nader will step down from the Audit Committee. Pursuant to the Company’s Non-Employee Director Compensation Policy (the “Policy”), the Board granted Ms.

    Read the 8-K filing
15. Jun 9, 2020

    In connection with the appointment of David W. Meline as Chief Financial Officer of the Company, effective June 8, 2020, Mr. Meline was designated as the Company’s principal financial officer and principal accounting officer, succeeding Lorence Kim and Jennifer Lee, respectively.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2025 · 2024 · 2023 · 2022

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.